|

A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

RECRUITINGSponsored by Ipsen
Actively Recruiting
SponsorIpsen
Started2026-07-10
Est. completion2031-09-30
Eligibility
Age6 Months+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07585097

Summary

This study will collect information from patients with ALGS who are using odevixibat in their daily lives. Odevixibat is a medication that helps patients with ALGS, a rare disease that affects the liver and causes itching. The main aim of this study is to observe the long-term, everyday safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.

Eligibility

Age: 6 Months+Healthy volunteers accepted
Inclusion Criteria:

* Diagnosed with ALGS.
* On (or starting) active odevixibat treatment.
* Aged 6 months or older at the time of consent.

Exclusion Criteria:

* Currently participating in a clinical trial with odevixibat.
* Currently participating in any interventional clinical trial for ALGS.
* Have any contraindication to odevixibat as per the locally approved label.

Conditions3

Alagille SyndromeHeart DiseaseLiver Disease

Browse More Trials

Heart Disease trialsLiver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.